Skip to main content
Top
Published in: Clinical Rheumatology 10/2018

01-10-2018 | Original Article

The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis

Authors: Ratanapha Phuan-udom, Nittaya Lektrakul, Wanruchada Katchamart

Published in: Clinical Rheumatology | Issue 10/2018

Login to get access

Abstract

As rheumatoid arthritis (RA) is an independent risk factor for osteoporotic fractures, the severity of disease activity may correlate with fracture risk. Our objectives were to determine the prevalence of major osteoporotic and hip fractures in patients with RA and to identify the factors related to their 10-year probabilities. This study enrolled 232 patients with RA, aged 40–90 years, who participated in the Siriraj RA Cohort in 2016 and 2017. Demographic data, disease activity scores 28 (DAS28), and health assessment questionnaires (HAQ) were collected. All participants were evaluated for asymptomatic vertebral fractures by thoracolumbar spine radiography. The osteoporotic fracture risks were determined using the fracture risk assessment tool (FRAX). Most subjects were postmenopausal women in their sixth decade; the median disease duration was 12.95 years. Forty-six percent of patients had osteoporotic fractures, and most (87%) were vertebral fractures. Eighty-one patients had asymptomatic vertebral compression fractures. Of those, 57%, 25%, and 18% had low, moderate, and high 10-year probabilities of major osteoporotic fractures, respectively, while 51%, 34%, and 15% had low, moderate, and high 10-year probabilities of hip fractures, respectively. Factors significantly associated with the 10-year probabilities of major osteoporotic and hip fractures were disease duration (p 0.017, 0.009), menopause duration (p < 0.001 both), cumulative disease activity (DAS28; p 0.004, 0.029), and cumulative functional disability (HAQ; p < 0.001 both). Moderate to high 10-year probabilities of major osteoporotic and hip fractures are common in RA. Cumulative disease severity is a high risk for osteoporotic fractures.
Literature
1.
go back to reference Engel A, Roberts J, Burch TA (1966) Rheumatoid arthritis in adults. Vital Health Stat 11:1–43 Engel A, Roberts J, Burch TA (1966) Rheumatoid arthritis in adults. Vital Health Stat 11:1–43
3.
go back to reference Wolfe AM (1968) The epidemiology of rheumatoid arthritis: a review. I. Surveys. Bull Rheum Dis 19:518–523PubMed Wolfe AM (1968) The epidemiology of rheumatoid arthritis: a review. I. Surveys. Bull Rheum Dis 19:518–523PubMed
4.
go back to reference Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P (1998) Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community oriented programme for the control of rheumatic disease. J Rheumatol 25:1382–1387PubMed Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P (1998) Epidemiology of rheumatic disease in rural Thailand: a WHO-ILAR COPCORD study. Community oriented programme for the control of rheumatic disease. J Rheumatol 25:1382–1387PubMed
5.
go back to reference Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494CrossRefPubMed Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494CrossRefPubMed
7.
go back to reference Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, el-zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRefPubMed Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, el-zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRefPubMed
8.
go back to reference (1991) Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 90:107–110 (1991) Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 90:107–110
10.
go back to reference Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522–530CrossRefPubMed Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522–530CrossRefPubMed
12.
go back to reference Haugeberg G, Orstavik RE, Kvien TK (2003) Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 15:469–475CrossRefPubMed Haugeberg G, Orstavik RE, Kvien TK (2003) Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 15:469–475CrossRefPubMed
13.
go back to reference Goldring SR, Gravallese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2:33–37CrossRefPubMed Goldring SR, Gravallese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2:33–37CrossRefPubMed
14.
go back to reference Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Orsolini G, Gatti D (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33:77–83PubMed Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Orsolini G, Gatti D (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33:77–83PubMed
15.
go back to reference Rossini M, Bagnato G, Frediani B et al (2011) Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J Rheumatol 38:997–1002CrossRefPubMed Rossini M, Bagnato G, Frediani B et al (2011) Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J Rheumatol 38:997–1002CrossRefPubMed
17.
go back to reference Kanis JA, Oden A, Johnell O, Johansson H, de Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, la Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMed Kanis JA, Oden A, Johnell O, Johansson H, de Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, la Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMed
20.
go back to reference Kanis JA, McCloskey EV, Johansson H et al (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413CrossRefPubMed Kanis JA, McCloskey EV, Johansson H et al (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413CrossRefPubMed
21.
go back to reference Brown JP, Josse RG, Canada TSAC of the OS of (2002) (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:s1–s34PubMedPubMedCentral Brown JP, Josse RG, Canada TSAC of the OS of (2002) (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:s1–s34PubMedPubMedCentral
22.
go back to reference Resnick D, Kransdorf MJ (2005) Bone and joint imaging. Elsevier Saunders Resnick D, Kransdorf MJ (2005) Bone and joint imaging. Elsevier Saunders
26.
go back to reference Osiri M, Deesomchok U, Tugwell P (2001) Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. Rheumatology (Oxford) 40:555–558CrossRef Osiri M, Deesomchok U, Tugwell P (2001) Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. Rheumatology (Oxford) 40:555–558CrossRef
27.
go back to reference Ibanez D, Urowitz MB, Gladman DD (2003) Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 30:1977–1982PubMed Ibanez D, Urowitz MB, Gladman DD (2003) Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 30:1977–1982PubMed
29.
go back to reference Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, Ichikawa N, Tanaka E, Momohara S, Nakajima A, Hara M, Tomatsu T, Yamanaka H, Kamatani N (2007) Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol 34:303–310PubMed Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, Ichikawa N, Tanaka E, Momohara S, Nakajima A, Hara M, Tomatsu T, Yamanaka H, Kamatani N (2007) Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol 34:303–310PubMed
30.
go back to reference Sinigaglia L, Nervetti A, Mela Q et al (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27:2582–2589PubMed Sinigaglia L, Nervetti A, Mela Q et al (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27:2582–2589PubMed
31.
go back to reference Mohammad A, Lohan D, Bergin D, Mooney S, Newell J, O'Donnell M, Coughlan RJ, Carey JJ (2014) The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53:821–827CrossRef Mohammad A, Lohan D, Bergin D, Mooney S, Newell J, O'Donnell M, Coughlan RJ, Carey JJ (2014) The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53:821–827CrossRef
32.
go back to reference Orstavik RE, Haugeberg G, Uhlig T et al (2004) Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 63:177–182CrossRefPubMedPubMedCentral Orstavik RE, Haugeberg G, Uhlig T et al (2004) Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 63:177–182CrossRefPubMedPubMedCentral
35.
go back to reference Orsolini G, Caimmi C, Viapiana O et al (2017) AB0216 Effects of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Ann Rheum Dis 76:1124 Orsolini G, Caimmi C, Viapiana O et al (2017) AB0216 Effects of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Ann Rheum Dis 76:1124
37.
go back to reference Méndez C, Silva L, Andreu JL et al (2013) AB0215 Risk markers of morphometric vertebral fracture in rheumatoid arthritis. Ann Rheum Dis 72:A852CrossRef Méndez C, Silva L, Andreu JL et al (2013) AB0215 Risk markers of morphometric vertebral fracture in rheumatoid arthritis. Ann Rheum Dis 72:A852CrossRef
39.
go back to reference El Maghraoui A, Rezqi A, Mounach A et al (2010) Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology 49:1303–1310CrossRefPubMed El Maghraoui A, Rezqi A, Mounach A et al (2010) Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology 49:1303–1310CrossRefPubMed
41.
go back to reference Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX® with and without bone mineral density. Calcif Tissue Int 90:1–13CrossRefPubMed Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX® with and without bone mineral density. Calcif Tissue Int 90:1–13CrossRefPubMed
Metadata
Title
The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis
Authors
Ratanapha Phuan-udom
Nittaya Lektrakul
Wanruchada Katchamart
Publication date
01-10-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 10/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4218-8

Other articles of this Issue 10/2018

Clinical Rheumatology 10/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.